These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 21214510)
61. Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase. Yen-Pon E; Li B; Acebrón-Garcia-de-Eulate M; Tomkiewicz-Raulet C; Dawson J; Lietha D; Frame MC; Coumoul X; Garbay C; Etheve-Quelquejeu M; Chen H ACS Chem Biol; 2018 Aug; 13(8):2067-2073. PubMed ID: 29897729 [TBL] [Abstract][Full Text] [Related]
62. Signal transduction by focal adhesion kinase in cancer. Zhao J; Guan JL Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797 [TBL] [Abstract][Full Text] [Related]
63. Identification of methyl violet 2B as a novel blocker of focal adhesion kinase signaling pathway in cancer cells. Kim H; Kim ND; Lee J; Han G; Sim T Biochem Biophys Res Commun; 2013 Jul; 437(2):319-24. PubMed ID: 23817042 [TBL] [Abstract][Full Text] [Related]
64. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach. Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434 [TBL] [Abstract][Full Text] [Related]
65. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875 [TBL] [Abstract][Full Text] [Related]
66. Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer. Zhang Y; Liu S; Zhou S; Yu D; Gu J; Qin Q; Cheng Y; Sun X Cancer Lett; 2021 Jan; 496():93-103. PubMed ID: 33038490 [TBL] [Abstract][Full Text] [Related]
67. New Insights on Fak and Fak Inhibitors. Brullo C; Tasso B Curr Med Chem; 2021; 28(17):3318-3338. PubMed ID: 33143618 [TBL] [Abstract][Full Text] [Related]
68. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Kornberg LJ Head Neck; 1998 Dec; 20(8):745-52. PubMed ID: 9790298 [TBL] [Abstract][Full Text] [Related]
69. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950 [TBL] [Abstract][Full Text] [Related]
70. Cellular characterization of a novel focal adhesion kinase inhibitor. Slack-Davis JK; Martin KH; Tilghman RW; Iwanicki M; Ung EJ; Autry C; Luzzio MJ; Cooper B; Kath JC; Roberts WG; Parsons JT J Biol Chem; 2007 May; 282(20):14845-52. PubMed ID: 17395594 [TBL] [Abstract][Full Text] [Related]
71. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Schultze A; Fiedler W Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362 [TBL] [Abstract][Full Text] [Related]
72. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth. Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415 [TBL] [Abstract][Full Text] [Related]
73. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction. Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592 [TBL] [Abstract][Full Text] [Related]
74. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study. Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280 [TBL] [Abstract][Full Text] [Related]
75. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway. Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854 [TBL] [Abstract][Full Text] [Related]
76. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Wendt MK; Schiemann WP Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433 [TBL] [Abstract][Full Text] [Related]
77. Protein kinase B/AKT and focal adhesion kinase: two close signaling partners in cancer. Wang S; Basson MD Anticancer Agents Med Chem; 2011 Dec; 11(10):993-1002. PubMed ID: 22023045 [TBL] [Abstract][Full Text] [Related]
78. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Garces CA; Kurenova EV; Golubovskaya VM; Cance WG Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200 [TBL] [Abstract][Full Text] [Related]
79. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase. Tsutsumi K; Kasaoka T; Park HM; Nishiyama H; Nakajima M; Honda T Int J Oncol; 2008 Jul; 33(1):215-24. PubMed ID: 18575768 [TBL] [Abstract][Full Text] [Related]
80. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Schultze A; Decker S; Otten J; Horst AK; Vohwinkel G; Schuch G; Bokemeyer C; Loges S; Fiedler W Invest New Drugs; 2010 Dec; 28(6):825-33. PubMed ID: 19784551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]